- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04918316
Initial Correction Keratoconus
Initial Correction Keratoconus: Scleral vs Corneal Gas Permeable Lenses SCOPE Study
Keratoconus is a non-inflammatory, progressive disease in which corneal irregularity increases. As the condition develops, more advanced forms of optical correction are needed to improve vision for patients. Until recently, small diameter corneal gas permeable lenses were considered the primary mode of correction for patients with keratoconus. Now, however, practitioners have multiple options for reducing the optical aberrations caused by keratoconus, including scleral lenses. As of yet, no single option for optical correction has been identified as the preferred mode of correction in terms of overall patient satisfaction with vision, comfort, and ease of use. The order in which various forms of optical correction would be most logically introduced has yet to be determined. This is a study comparing small diameter corneal gas permeable and large diameter scleral lenses in individuals with keratoconus.
This study will prospectively compare visual satisfaction and ease of use between corneal gas permeable and scleral lenses for patients with mild to moderate keratoconus.
Study Overview
Detailed Description
While both corneal gas permeable and scleral lenses have been show to improve visual acuity in individuals with keratoconus, it has yet to be determined if one option has superior comfort and overall patient satisfaction in patients new to gas permeable lens use. In this study, patients will be prospectively fit with both corneal gas permeable and scleral lenses according to standard clinical practice. Both corneal gas permeable and scleral lenses are considered standard of care for patients with keratoconus.
The investigators hypothesize that study participants will select scleral lens over corneal gas permeable lens as their preferred final lens type of choice.
The Primary outcome measure of this study is participant selected final lens choice for continued use for the management of keratoconus.
Methods:
Study Design This is a prospective, multi-center, randomized interventional clinical trial with a 2x2 crossover design of patients with keratoconus fit with corneal and scleral gas permeable contact lenses. The crossover design allows intra-subject differences between two randomized groups with participants serving as their own controls. Contact lens #1 will be the SynergEyes VS (Synergeyes, Inc., Carlsbad CA) which features bi-tangential toric peripheries with linear landing zones. The standard lens is 16.0mm and is available from 14.5 to 17.5mm diameters. Contact lens #2 will be the RoseK2 corneal gas permeable lens (Blanchard Contact Lens, Inc. Manchester, NH). The lens is available in with a base curve range from 4.30 to 8.60 mm, diameter of 7.90 to 10.40mm.
Inclusion Criteria
- Age 18 or older.
- Diagnosis of keratoconus.
- Available baseline corneal topography and pachymetry
- Amsler-Krumeich keratoconus classification of stage 1 or higher
Exclusion Criteria
- No prior corneal transplantation or INTACTS
- No prior use of hybrid, corneal or scleral gas permeable lenses
- Presence of corneal scarring
Study procedures During the initial study visits patient demographics, past ocular and medical history and best corrected visual acuity with manifest refraction will be recorded. Additional testing may include corneal topography, pachymetry and meibography. Dry eye symptoms and contact lens comfort will be assessed using the OSDI and CLDEQ questionnaires.
Participants will be fit according to standard practices with the RoseK 2 corneal gas permeable and Synergeyes VS scleral lenses following manufacturer's recommendations. Over refraction and best corrected visual acuity will be recorded. Subjective comfort with lens use rated on comfort scale of 0 (not comfortable) to 10 (very comfortable).
Participants will be randomized to dispense lens #1 vs lens #2. They will be trained in safe application and removal and provided instructions on lens disinfection procedures. Best corrected visual acuity with lens #1 and subjective comfort with lens use will be rated on comfort scale of 0 (not comfortable) to 10 (very comfortable).
At the next visit, participants will return wearing lens #1 for minimum of 3 hours. Best corrected visual acuity with lens #1 will be recorded as well as hours of lens wear today, average hours of lens wear time, days per week of per week and daily time spent on lens application and removal. They will rate subjective comfort with lens use on comfort scale of 0 (not comfortable) to 10 (very comfortable). Dry eye symptoms will be assessed using OSDI and CLDEQ questionnaires. Participants will be trained in application and removal with lens #2. Best corrected visual acuity with lens #2 and subjective comfort will be rated on comfort scale of 0 (not comfortable) to 10 (very comfortable).
At the final visit, participants will return wearing lens #2 for minimum of 3 hours. Best corrected visual acuity with lens #2 will be recorded as well as hours of lens wear today, average hours of lens wear time, days per week of per week and daily time spent on lens application and removal. They will rate subjective comfort with lens use on comfort scale of 0 (not comfortable) to 10 (very comfortable). Dry eye symptoms will be assessed using OSDI and CLDEQ questionnaires. Participants will be trained in application and removal with lens #2. Best corrected visual acuity with lens #2 and subjective comfort will be rated on comfort scale of 0 (not comfortable) to 10 (very comfortable).
The participant will make a final selection of lens of choice #1 or #2.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ellen S Shorter, OD
- Phone Number: 312-996-5410
- Email: eshorter@uic.edu
Study Contact Backup
- Name: Bhavana Kolli, MHA
- Phone Number: 312-996-7182
- Email: bkolli2@uic.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- University of Illinois at Chicago Eye and Ear Infirmary
-
Contact:
- Ellen Shorter, OD
- Phone Number: 312-996-5410
- Email: eshorter@uic.edu
-
Chicago, Illinois, United States, 60616
- Recruiting
- Illinois Eye Institute
-
Contact:
- Jennifer Harthan, OD
-
Principal Investigator:
- Jennifer Harthan, OD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Cherie Nau, OD
-
Principal Investigator:
- Cherie Nau, OD
-
Sub-Investigator:
- Muriel Schornack, OD
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University College of Optometry
-
Principal Investigator:
- Jennifer Fogt, OD, MS
-
Contact:
- Jennifer Fogt, OD, MS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of keratoconus
- Available baseline corneal topography and pachymetry
- Amsler-Krumeich keratoconus classification9 of stage 1
Exclusion Criteria:
- No prior corneal transplantation or INTACTS
- No prior use of hybrid, corneal or scleral gas permeable lenses
- Presence of corneal scarring.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Corneal gas permeable lens first
Device: corneal gas permeable contact lenses (RoseK2 corneal Blanchard Contact Lens, Inc. Manchester, NH). Participants with an odd study ID will be fit with the corneal gas permeable lens first. |
Fit in corneal gas permeable contact lens first.
|
Active Comparator: Scleral lens first
Device: scleral lenses (SynergEyes VS (Synergeyes, Inc., Carlsbad CA). Participants with an even study ID will be fit with the scleral lens first. |
Fit in corneal gas permeable contact lens first.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Final contact lens choice
Time Frame: At study completion (6-24 weeks)
|
Each study participant will select whether to continue with Lens 1 or Lens 2. The percentage of those who choose a Scleral Lens will be compared to the percentage of participants who select corneal gas permeable lenses.
|
At study completion (6-24 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective comfort with lens use
Time Frame: Baseline, Study Visit 1 (2-4 weeks), Study Visit 2 (4-10 weeks) and at study completion (6-24 weeks)
|
Subjective comfort with lens use will be rated by participants on comfort scale of 0 (not comfortable) to 10 (very comfortable).
|
Baseline, Study Visit 1 (2-4 weeks), Study Visit 2 (4-10 weeks) and at study completion (6-24 weeks)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ellen S Shorter, OD, University of Illinois at Chicago
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-1504
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keratoconus
-
The Cleveland ClinicUniversity of MarylandEnrolling by invitationKeratoconus | Keratoconus, Unstable | Keratoconus, StableUnited States
-
Eye Hospital Pristina KosovoActive, not recruitingKeratoconus | Keratoconus of Right Eye | Keratoconus, Unstable, Right EyeKosovo
-
Tianjin Eye HospitalRecruitingScansys, Pentacam, Keratoconus, Subclinical KeratoconusChina
-
Tianjin Eye HospitalActive, not recruitingScansys, Pentacam, Corvis ST, Keratoconus, Subclinical KeratoconusChina
-
Heba Allah Nashaat MohamedAssiut UniversityRecruitingKeratoconus, CollagenEgypt
-
Kent Wellish MDNot yet recruitingKeratoconus, Unstable
-
Kasr El Aini HospitalUnknownProgressive KeratoconusEgypt
-
Centre Hospitalier Régional Metz-ThionvilleCompletedProgressive Keratoconus
-
Glaukos CorporationCompletedProgressive KeratoconusUnited States
-
Tianjin Eye HospitalCompletedKeratoconus, StableChina
Clinical Trials on Corneal gas permeable lens
-
London South Bank UniversityCompletedKeratoconus | Irregular Astigmatism | Irregular; Contour of Cornea | Pellucid Marginal Corneal Degeneration | Injury of CorneaUnited Kingdom
-
Taipei Medical University HospitalUnknown
-
Shanghai Eye Disease Prevention and Treatment CenterShanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Shandong University of Traditional Chinese MedicineNot yet recruiting
-
Stanford UniversityNational Eye Institute (NEI); Bausch & Lomb Incorporated; Alcon Research; BSN-JOBST... and other collaboratorsCompleted
-
Alcon ResearchCompletedRefractive Error | Astigmatism | Myopia | Hyperopia
-
The Hong Kong Polytechnic UniversityMenicon Co., Ltd.Active, not recruitingMyopic ProgressionHong Kong
-
The Hong Kong Polytechnic UniversityMenicon Co., Ltd.Active, not recruitingMyopic ProgressionHong Kong
-
Ashford and St. Peter's Hospitals NHS TrustBausch & Lomb IncorporatedUnknown
-
Batman Training and Research HospitalCompletedMacula Edema | Menopause Surgical | Visual Acuity Reduced TransientlyTurkey
-
Wenzhou Medical UniversityCompletedMicrocornea Within One Year of AgeChina